Notably, compared with febuxostat and allopurinol, benzbromarone has a lower risk of cardiovascular events, although this difference did not reach statistical significance.
1
—
—
Notably, compared with febuxostat and allopurinol, benzbromarone has a lower risk of cardiovascular events, although this difference did not reach statistical significance.